Table 4 Criteria for prioritisation of health technology reassessment in the main countries reviewed
From: A systematic review on current status of health technology reassessment: insights for South Korea
| Â | United Kingdom | Canada | Australia | Spain |
|---|---|---|---|---|
Prioritisation | - Budget impact - Existing alternatives - Improved patient safety - Not for vulnerable populations - Small benefit - Close risk/benefit ratio | - Cost of service - Potential impact - Cost-effective alternative - Disease burden - Sufficient evidence available - Scope for time-limited funding with “pay for evidence” or “only in research” provisions - Futility | - Cost of service - Potential impact - Cost-effective alternative - Disease burden - Sufficient evidence available - Scope for time-limited funding with “pay for evidence” or “only in research” provisions - Futility | Population/users - Disease frequency - Burden of disease - Frequency of technology use - Patients preferences Risk/benefit - Efficacy/effectiveness/validity - Adverse effects - Risks Costs, organisation, other implications - Efficiency - Maintenance costs - Other implications |